{
    "clinical_study": {
        "@rank": "119506", 
        "arm_group": [
            {
                "arm_group_label": "ACT01 plus Comp01", 
                "arm_group_type": "Placebo Comparator", 
                "description": "ACT01 Cream in combination with Comp01 Cream, once daily, 29 days"
            }, 
            {
                "arm_group_label": "ACT01 plus Comp02", 
                "arm_group_type": "Active Comparator", 
                "description": "ACT01 Cream in combination with Comp02 Cream, once daily, 29 days"
            }, 
            {
                "arm_group_label": "ACT01 plus Comp03", 
                "arm_group_type": "Active Comparator", 
                "description": "ACT01 Cream in combination with Comp03 Cream, once daily, 29 days"
            }, 
            {
                "arm_group_label": "ACT01 plus Comp04", 
                "arm_group_type": "Other", 
                "description": "ACT01 Cream in combination with Comp04 Cream, once daily, 29 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether or not ACT01 is effective and tolerable\n      alone or when used in combination with Comp01, Comp02, Comp03 or Comp04 in patients with\n      facial and/or scalp keratosis."
        }, 
        "brief_title": "ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis", 
        "condition": "Actinic Keratosis", 
        "condition_browse": {
            "mesh_term": [
                "Keratosis", 
                "Keratosis, Actinic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Presence of actinic keratosis lesions on the face and/or scalp within a 25 cm2\n             contiguous area containing at least four lesions that are non-hypertrophic and\n             non-hyperkeratotic and not larger than 6 mm in longest diameter.\n\n          2. Age 30-85 years, inclusive.\n\n          3. Good general health as determined by investigator and supported by medical history\n             and normal or not clinically significant abnormal vital signs (blood pressure and\n             pulse).\n\n        Exclusion Criteria:\n\n          1. Severe, uncontrolled auto-immune, cardiovascular, gastrointestinal, hematological,\n             hepatic, neurological, pancreatic, pulmonary or renal disease.\n\n          2. Dermatologic conditions if present on the face such as acne, atopic dermatitis,\n             seborrheic dermatitis, eczema, rosacea, or albinism.\n\n          3. Application of 1) chemical peel, 2) dermabrasion, 3) laser abrasion, 4) PUVA\n             (psoralen plus ultraviolet A) therapy, or 5) UVB therapy to the intended treatment\n             area within 180 days prior to the Baseline Visit.\n\n          4. Use of sun lamps or sun tanning beds or booths during the 14 days prior to the\n             Baseline Visit."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02126670", 
            "org_study_id": "NP1401"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ACT01 plus Comp01", 
                    "ACT01 plus Comp02", 
                    "ACT01 plus Comp03", 
                    "ACT01 plus Comp04"
                ], 
                "intervention_name": "ACT01", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ACT01 plus Comp01", 
                "intervention_name": "Comp01", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ACT01 plus Comp02", 
                "intervention_name": "Comp02", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ACT01 plus Comp03", 
                "intervention_name": "Comp03", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ACT01 plus Comp04", 
                "intervention_name": "Comp04", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92123"
                    }, 
                    "name": "Therapeutics Clinical Research"
                }, 
                "investigator": {
                    "last_name": "Neil Bhatia, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40202"
                    }, 
                    "name": "Dermatology Specialists Research, LLC"
                }, 
                "investigator": {
                    "last_name": "Mark J Jackson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "High Point", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27262"
                    }, 
                    "name": "Dermatology Consulting Services; Zoe Diana Draelos, MD"
                }, 
                "investigator": {
                    "last_name": "Zoe D Draelos, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37215"
                    }, 
                    "name": "Tennessee Clinical Research Center"
                }, 
                "investigator": {
                    "last_name": "Michael H Gold, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "overall_contact": {
            "email": "kgulbronson@promiuspharma.com", 
            "last_name": "Kendra Gulbronson, MS", 
            "phone": "609-282-1476"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Actinic keratoses lesion count", 
            "safety_issue": "No", 
            "time_frame": "up to Day 57"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02126670"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Irritation in the treatment area will be graded as none, mild, moderate or severe.", 
            "measure": "Irritation score", 
            "safety_issue": "Yes", 
            "time_frame": "Day 1, Day 8, Day 29, Day 57"
        }, 
        "source": "Promius Pharma, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Promius Pharma, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}